Zydus Urosciences, a speciality division of Cadila Healthcare (Zydus), on Wednesday announced the launch of Udenafil, a therapy for the treatment of ED (erectile dysfunction) under the brand name 'Udzire'.
The group has an exclusive license to market this patented molecule developed by Dong-A Pharmaceuticals of Korea, in India, Zydus said in a statement to the Bombay Stock Exchange on Wednesday.
Udenafil, a newly deveoped PDE5 (Phosphodiesterase 5) inhibitor approved for the treatment of ED, is the fourth amongst the PDE5 inhibitors class and has a better tolerability profile, the company claimed.
Currently, only two molecules, sildenafil and tadalafil from this group are available for the treatment of ED in India. Sildenafil has a rapid onset of action but duration of action is shorter. Tadalafil has a longer duration of action but is associated with side effects of muscle pain and back pain. Zydus said that Udenafil has been found efficacious in the treatment of various causes and severity of ED with no muscle or back pain being reported in the clinical trials.
